Pediatric Exclusivity Changes Should Be Minimal In Reauthorization - FDA
Executive Summary
FDA should consider supporting "wild card" pediatric exclusivity which would allow companies to apply patent extensions to a product of their choice in return for performing needed pediatric research, Oncologic Drugs Advisory Committee member Henry Friedman, MD, Duke University Medical Center, suggested.
You may also be interested in...
Pediatric Studies Could Be Required For Most Lymphomas, Leukemia
FDA may invoke the pediatric rule to require studies for most lymphomas and leukemias, members of the Oncologic Drugs Advisory Committee's Pediatric Subcommittee recommended April 24.
Pediatric Studies Could Be Required For Most Lymphomas, Leukemia
FDA may invoke the pediatric rule to require studies for most lymphomas and leukemias, members of the Oncologic Drugs Advisory Committee's Pediatric Subcommittee recommended April 24.
FDA Considering Exclusivity Program As Antimicrobial Development Incentive
A drug exclusivity program is being considered by FDA as an incentive to encourage investment in antimicrobial product development, FDA Commissioner Henney, MD, indicated during a Senate Appropriations/Labor, HHS & Education subcommittee hearing Sept. 20.